360° SearchNetwork Hot Spots Trends Time Series

Repros Therapeutics Inc

Type: Company

Name: Repros Therapeutics Inc

First reported May 23 2013 - Updated 16 hours ago - 3 reports

FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids

CONTACT: Repros Therapeutics Inc.Joseph Podolski (281) 719-3447President and Chief Executive OfficerInvestor Relations: Thomas HoffmannThe Trout Group(646) 378-2931 ... [Published Reuters - May 23 2013]

Entities: Phase IIb, Repros Therapeutics Inc, The Trout Group

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Bullish Moving Average Cross by Repros Therapeutics (RPRX)

(Financial News Network On) Repros Therapeutics (NASDAQ:RPRX) crossed over its 10-day moving average of $16.75 on a volume of 226K shares. This may provide short-term investors a chance for a long position, as such a crossover often suggests higher prices ... [Published Individual.com - May 22 2013]

Entities: Repros Therapeutics Inc, Moving Average, Long Position

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Repros Therapeutics Shares Climbing...

One of today's stocks on the move is Repros Therapeutics (NASDAQ:RPRX), up 2.9% to $15.45. The Dow Jones Industrial Average is now trading 13,026 and the S&P is trading 1,416. Repros Therapeutics share prices have moved between a 52-week high of $17.00 ... [Published Financial News Network online - May 21 2013]

Entities: Repros Therapeutics Inc, Stocks, Dow Jones Industrial Average, Moving Average

First reported May 19 2013 - Updated May 19 2013 - 1 reports

Aegerion Pharmaceuticals Inc

The Best- And Worst- Performing Biotech Stocks, May 10 To May 17

These are the best and worst-performing medical and biotech stocks from May 10 to May 17, 2013. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had market capitalizations ... [Published Forbes.com - May 19 2013]

Entities: Biotechnology, Stocks, Aegerion Pharmaceuticals Inc

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Form 8-K REPROS THERAPEUTICS INC. For: May 16

StreetInsider.com - Form 8-K REPROS THERAPEUTICS INC. For: May 16 ... [Published Street Insider - May 16 2013]

Entities: Repros Therapeutics Inc, 8-k

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Repros Therapeutics Price Target Raised to $23.00 at Ascendiant Capital Markets (RPRX)

Equities research analysts at Ascendiant Capital Markets increased their price target on shares of Repros Therapeutics (NASDAQ: RPRX)Other equities research analysts have also recently issued reports about the stock. Analysts at Roth Capital raised their ... [Published American Banking News - Stock Ratings - May 14 2013]

Entities: Repros Therapeutics Inc, Capital Markets, Stocks, Earnings Per Share

First reported May 10 2013 - Updated May 11 2013 - 3 reports

Repros Therapeutics Inc. (RPRX) Reports First Quarter 2013 Financial Results

Staying up-to-date has never been simpler. Sign up for the today! THE WOODLANDS, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Â® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2013. Help employers find you! Check out ... [Published BioSpace - May 11 2013]

Entities: Repros Therapeutics Inc

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Repros Therapeutics (RPRX) moves higher despite loss

Repros Therapeutics Inc (NASDAQ: RPRX) shares gained 0.5% to $18.37, after announcing a quarterly net loss of $7.4 million, or $0.41 per share, as compared to a net loss of $2.4 million, or $0.17 per share, for the same period in 2012. Share volume was ... [Published BayStreet.ca - May 10 2013]

Entities: Repros Therapeutics Inc, Stocks

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Repros Therapeutics (RPRX) Releases Quarterly Earnings Results

Repros Therapeutics (NASDAQ: RPRX) posted its quarterly earnings results on Friday. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.35) by $0.06, ARN reports.RPRX has been the subject of a number ... [Published American Banking News - Earnings - May 10 2013]

Entities: Repros Therapeutics Inc, Roth Capital Partners, Stocks, Lazard Capital Markets

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Form 8-K REPROS THERAPEUTICS INC. For: May 10

StreetInsider.com - Form 8-K REPROS THERAPEUTICS INC. For: May 1 ... [Published Street Insider - May 10 2013]

Entities: Repros Therapeutics Inc, 8-k

First reported Apr 29 2013 - Updated Apr 29 2013 - 3 reports

REPROS THERAPEUTICS INC: Repros to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

Joseph Podolski (281) 719-3447President and Chief Executive Officer Repros to Present at the Bank of America Merrill Lynch 2013 Health Care ConferenceTHE WOODLANDS, Texas - April 29, 2013 - Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that ... [Published 4 Traders - Apr 29 2013]

Entities: Repros Therapeutics Inc, Bank of America Merrill Lynch, Health Care

First reported Apr 29 2013 - Updated Apr 29 2013 - 3 reports

Repros Proellex(R) in Breast Cancer Phase 2 Study in . . .

Repros' Proellex(R) in Breast Cancer Phase 2 Study in Collaboration With Northwestern UniversityGlobeNewswireTHE WOODLANDS, Texas, April 29, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) announced it is collaborating with Feinberg School ... [Published Equities.com - Apr 29 2013]

Entities: Breast Cancer, Repros Therapeutics Inc, Phase II, Apoptosis, Northwestern University

Quotes

Professor Alfred Poindexter, MD, Department of OB/GYN, Baylor College of Medicine, noted, "The early experience generated at my clinical site with vaginally administered telapristone suggests that Proellex-V may represent a useful, effective, safe and patient friendly option for the treatment of uterine fibroids in those women opting away from surgery in order to resolve their fibroid associated symptoms. The reduction of tumor size at the 12 mg dose was particularly impressive and will be an important consideration to both physicians and patients alike. Currently several of my subjects are in the third cycle of treatment using the 12 mg dose and are experiencing persistent benefit and have expressed a desire to continue treatment after the +1 year of exposure to telapristone which will be completed later this year."

FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleed ... [Published OSIX News - May 23 2013]

...true entrepreneurial spirit which has made Houston the hub for innovation," said Walter Ulrich, president and CEO of the Houston Technology Center. "Vijay and Marie are such a gracious, generous and successful couple, and mean so much to the Houston community with their philanthropy. We are grateful for his and his foundation's dedication and leadership. Entrepreneurs are the engine of our economy and have built Houston to be a dynamic and diverse region well known for our energy, aerospace, life sciences and technology sectors. We are pleased to continue our annual tradition of celebrating these outstanding entrepreneurs" said Ulrich. The 10th Gala celebrated entrepreneurs included:

Texas' Largest Technology Accelerator Honors Extraordinary Entrepreneurs [Published TickerTech.com - May 21 2013]

"Joe wouldn't have come up with the idea for Androxal without having met me... He has a very weak patent. There's a 90% likelihood that the Repros patent will be challenged and will not survive. My patent, however, will survive."

Repros Patent Problems Began When Harry Met Joe [Published TheStreet.com - May 09 2013]

...This restoration of organ function is a unique feature of Androxal compared to the approved hormone replacement therapies." He further noted, "Today the Endocrine Society recommends that physicians assess testosterone levels in men suspected to be Type 2 diabetic or pre-diabetic. Androxal offers a rational approach to treat the hypogonadal diabetic male. Endocrinologists represent a special population of readily reached physicians that may be the first adopters of Androxal in the treatment of hypogonadism."

Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents [Published Asian Hospital & Healthcare Management - Apr 29 2013]

More Content

sort by: Date \| Relevance
Lower open seen for TSX [Published Yahoo! Canada - 1 hour ago]
Repros to Conduct Phase IIb Trial Zacks [Published Yahoo! Finance - 16 hours ago]
US EQUITIES OPENING HEADLINES INCLUDING: Micros... [Published Proactiveinvestors United Kingdom RSS feed - 23 hours ago]
FDA Recommends Running Phase 2b Trial of Repros... [Published Benzinga.com - May 23 2013]
FDA Recommends Running Phase 2b Trial of Proell... [Published GlobeNewswire: Acquisitions News - May 23 2013]
FDA Recommends Running Phase 2b Trial of Proell... [Published Reuters - May 23 2013]
FDA Recommends Running Phase 2b Trial of Proell... [Published OSIX News - May 23 2013]
FDA Recommends Running Phase 2b Trial of Proell... [Published Stockwatch - May 23 2013]
Bullish Moving Average Cross by Repros Therapeu... [Published Individual.com - May 22 2013]
Texas' Largest Technology Accelerator Honors Ex... [Published TickerTech.com - May 21 2013]
Repros Therapeutics Shares Climbing... [Published Financial News Network online - May 21 2013]
The Best- And Worst- Performing Biotech Stocks,... [Published Forbes.com - May 19 2013]
Form 8-K REPROS THERAPEUTICS INC. For: May 16 [Published Street Insider - May 16 2013]
Exclusive Q&A With a Woman Pioneer in Biotech [Published Forbes.com - May 15 2013]
Repros Therapeutics Price Target Raised to $23.... [Published American Banking News - Stock Ratings - May 14 2013]
Repros Therapeutics Inc. (RPRX) Reports First Q... [Published BioSpace - May 11 2013]
Healthcare Review: Sirona Dental Systems, Roset... [Published BioMedReports - May 10 2013]
Repros Therapeutics Inc. Reports First Quarter ... [Published BioSpace - May 10 2013]
Repros Therapeutics (RPRX) moves higher despite... [Published BayStreet.ca - May 10 2013]
U.S./Canada daily earnings hits & misses May 10... [Published Globe and Mail - May 10 2013]
Repros Therapeutics (RPRX) Releases Quarterly E... [Published American Banking News - Earnings - May 10 2013]
Repros Therapeutics (RPRX): Q1 EPS of -$0.41 mi... [Published Seeking Alpha - May 10 2013]
Repros Therapeutics Inc.(R) Reports First Quart... [Published GlobeNewswire: Advertising News - May 10 2013]
Repros Therapeutics Inc.(R) Reports First Quart... [Published Reuters - May 10 2013]
Repros Therapeutics Inc.(R) Reports First Quart... [Published Interest!ALERT - May 10 2013]
Form 8-K REPROS THERAPEUTICS INC. For: May 10 [Published Street Insider - May 10 2013]
Biotech Stock Mailbag: Synta, Zogenix, Sarepta,... [Published TheStreet.com - May 10 2013]
Repros Therapeutics Price Target Raised to $31.... [Published American Banking News - May 10 2013]
Repros Patent Problems Began When Harry Met Joe [Published BioPortfolio - May 09 2013]
Repros Patent Problems Began When Harry Met Joe [Published TheStreet.com - May 09 2013]

Blogs

sort by: Date \| Relevance
Analysts: BlackBerry Rates Were Unimpressive an... [Published Wall St. Cheat Sheet - Apr 01 2013] BlackBerry ( NASDAQ:BBRY ): According to William Blair, BlackBerry 10 sell-through rates were unimpressive, and the firm also states that the long-term viability of the BlackBerry’s business model is based on Blackberry 10 sales. The firm continues ...
Hot Stocks: FreeSeas, Cell Therapeutics, Excel ... [Published MaritimeSecurity.Asia - Mar 29 2013] Houston, TX – March 28, 2013 – (MESHPRESS) – H oleinonestocks.net , an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:- FreeSeas ...
Hot Stocks: FreeSeas, Cell Therapeutics, Excel ... [Published MaritimeSecurity.Asia - Mar 29 2013] Houston, TX – March 28, 2013 – (MESHPRESS) – H oleinonestocks.net , an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:- FreeSeas ...
Market Close: Big Winners & Losers for March 28... [Published 24/7 Wall St. - Mar 28 2013] Here are today’s five biggest gaining stocks at closing: Repros Therapeutics Inc. (NASDAQ: RPRX) is up 76.3% at $16.10. LiveDeal Inc. (NASDAQ: LIVE) is up 35.4% at $3.67. Mecox Lane Ltd. (NASDAQ:... ...
Stocks to Watch: Research In Motion, Repros, Fi... [Published WSJ.com: MarketBeat - Mar 28 2013] Among the companies with shares expected to actively trade in Thursday's session are Research In Motion, Repros Therapeutics and Five Below. ...

Press Releases

sort by: Date \| Relevance
FDA Recommends Running Phase 2b Trial of Proell... [Published GlobeNewswire: Acquisitions News - May 23 2013]
Repros Therapeutics Inc.(R) Reports First Quart... [Published GlobeNewswire: Advertising News - May 10 2013]
Repros Reports Second Pivotal Androxal(R) Study... [Published GlobeNewswire: Acquisitions News - May 02 2013]
Repros' Proellex(R) in Breast Cancer Phase 2 St... [Published GlobeNewswire: Acquisitions News - Apr 29 2013]
Repros to Present at the Bank of America Merril... [Published GlobeNewswire: Advertising News - Apr 29 2013]